LAS VEGAS–(BUSINESS WIRE)–Avant Technologies, Inc. (OTCQB: AVAI) (“Avant” or the “Company”), an emerging biotechnology company focused on developing cellbased therapies for diabetes and age-related disorders, today announced that its 50/50 joint venture (Klothonova) with Austrianova has entered into an exclusive, worldwide License Agreement with Klothea Bio, Inc. The license agreement, effective immediately, grants Klothonova exclusive global rights to develop, manufacture, and commercialize.
This excerpt is quoted from the original release. Read the full announcement on Business Wire.
Brief Summary
Avant Technologies, Inc. (OTCQB: AVAI), an innovative biotech company, has entered into a significant industrial partnership. Their joint venture, Klothonova with Austrianova, has secured a worldwide exclusive license from Klothea Bio, Inc. to develop groundbreaking Klotho-producing cell lines.
- Exclusive Global Rights: Klothonova can now develop and commercialize Klotho cell lines.
- Focus on Aging: The licensing aims to advance anti-aging therapies.
- Innovative Approach: The partnership could revolutionize treatments for age-related disorders.
Why it matters: This collaboration positions Avant Technologies at the forefront of biotechnology innovations, potentially increasing value for investors.
Read the Full Article
This is a summary of the press release. For the complete article and any additional details, please visit the original source.
Attribution: Original press release by Business Wire on . We provide an AI-generated summary and links for convenience. Always verify details with the original source. Not investment advice. For informational purposes only.